Lacosamide Teva

Lacosamide, the active ingredient in Lacosamide Teva, is an anticonvulsant presented as an oral tablet for oral use. It treats partial‑onset seizures in patients with epilepsy.

GNH USA supplies Lacosamide Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anticonvulsant indicated for seizure disorders and is used as adjunct therapy in epilepsy.

Partial‑onset seizures: reduces seizure frequency when added to existing antiepileptic regimens. Epilepsy (adjunctive therapy): improves overall seizure control in patients with refractory epilepsy. Focal epilepsy: serves as a supplemental option for patients who have not achieved adequate control with first‑line agents.

Lacosamide may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Dizziness - Nausea - Headache - Fatigue - Blurred vision - Diplopia

Serious or Rare Side Effects: - Cardiac arrhythmias, including atrial fibrillation - Severe skin reactions such as Stevens‑Johnson syndrome - Suicidal thoughts or behavior - Hypersensitivity reactions (rash, angioedema) - Elevated liver enzymes - Respiratory depression when combined with other CNS depressants

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

Monitor cardiac function: obtain baseline ECG and watch for arrhythmias. Assess renal function: adjust dose in patients with severe impairment. Review concomitant CNS depressants: avoid excessive sedation. Use caution in hepatic impairment: monitor liver enzymes periodically. Avoid abrupt discontinuation: taper gradually to reduce seizure recurrence risk. Store at room temperature: keep in the original pack, protect from moisture.

Lacosamide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin) may markedly reduce lacosamide plasma levels. - Co‑administration with other sodium‑channel blockers can increase central nervous system depression. - Concurrent use of QT‑prolonging agents may heighten the risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Oral contraceptives: lacosamide may lower hormonal efficacy, consider alternative contraception. - Alcohol: combined use can exacerbate dizziness and sedation. - Certain antidepressants (e.g., tricyclics): may increase the likelihood of hyponatremia.